Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
AssigneeJazz Pharmaceuticals Research UK Limited
InventorsDaniel Adam Checketts, Kevin James Craig
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are experienced in patients diagnosed with Cortical Dysplasia and Cortical Brain Malformation. In a further embodiment the types of seizures include atonic, tonic, and focal without impairment seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
Claims13
A method of treating seizures associated with Cortical Brain Malformation, wherein the seizures associated with Cortical Brain Malformation are atonic, tonic, and focal without impairment seizures comprising administering a cannabidiol (CBD) drug substance, wherein the CBD drug substance comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC), wherein the CBD drug substance provides a dose of CBD in the range of 5 mg/kg/day to 50 mg/kg/day.
Dependencies are inferred from the claim text.